Evercore ISI Adjusts Price Target on Incyte to $110 From $73, Maintains In Line Rating

robot
Abstract generation in progress

Evercore ISI has increased its price target for Incyte Corporation (NASDAQ: INCY) shares to $110 from $73, while maintaining an “In Line” rating. This adjustment reflects a significant uplift in the analyst’s valuation of the pharmaceutical company, which specializes in cancer and inflammatory disorder treatments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin